Structure-activity relationship of dihydropyridines for rhabdomyosarcoma
Biochemical and Biophysical Research Communications · 2023
DOI: 10.1016/j.bbrc.2023.04.114 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2023. Verfasst von Shefali Chauhan und 14 weiteren Autor:innen. Beteiligte Einrichtung: Children's Cancer Therapy Development Institute, Beaverton, OR, 97005, USA. Electronic address: shefali@cc-tdi.org. Hauptthemen laut MEDLINE: Rhabdomyosarcoma, Dihydropyridines. Die Arbeit nennt 21 Literaturangaben.
Abstract (Originalsprache)
Childhood muscle-related cancer rhabdomyosarcoma is a rare disease with a 50-year unmet clinical need for the patients presented with advanced disease. The rarity of ∼350 cases per year in North America generally diminishes the viability of large-scale, pharmaceutical industry driven drug development efforts for rhabdomyosarcoma. In this study, we performed a large-scale screen of 640,000 compounds to identify the dihydropyridine (DHP) class of anti-hypertensives as a priority compound hit. A structure-activity relationship was uncovered with increasing cell growth inhibition as side chain length increases at the ortho and para positions of the parent DHP molecule. Growth inhibition was consistent across n = 21 rhabdomyosarcoma cell line models. Anti-tumor activity in vitro was paralleled by studies in vivo. The unexpected finding was that the action of DHPs appears to be other than on the DHP receptor (i.e., L-type voltage-gated calcium channel). These findings provide the basis of a medicinal chemistry program to develop dihydropyridine derivatives that retain anti-rhabdomyosarcoma activity without anti-hypertensive effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Children's Cancer Therapy Development Institute, Beaverton, OR, 97005, USA. Electronic address: shefali@cc-tdi.org.
- Children's Cancer Therapy Development Institute, Beaverton, OR, 97005, USA.
- ApconiX Ltd, Alderley Park, Nether Alderley, Cheshire, SK10 4TG, UK.
- Genomics Institute of the Novartis Research Foundation, San Diego, CA, 92121, USA.
- Children's Cancer Therapy Development Institute, Beaverton, OR, 97005, USA. Electronic address: charles@cc-tdi.org.
Zitieren
APA
Chauhan, S., Woods, A. D., Bharathy, N., Lian, X., Ricker, C. A., Mantz, A., Zuercher, W. J., Price, L. H., Morton, M. J., Durrant, E., Corbel, S. Y., Sampath, S. C., Sampath, S. C., Joslin, J., & Keller, C. (2023). Structure-activity relationship of dihydropyridines for rhabdomyosarcoma. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2023.04.114
Vancouver
Chauhan S, Woods AD, Bharathy N, Lian X, Ricker CA, Mantz A, et al. Structure-activity relationship of dihydropyridines for rhabdomyosarcoma. Biochemical and Biophysical Research Communications. 2023. doi:10.1016/j.bbrc.2023.04.114
BibTeX
@article{Chauhan2023,
author = {Chauhan, Shefali and Woods, Andrew D and Bharathy, Narendra and Lian, Xiaolei and Ricker, Cora A and Mantz, Amy and Zuercher, William J and Price, Lisa H and Morton, Michael J and Durrant, Eric and Corbel, Stéphane Y and Sampath, Srinath C and Sampath, Srihari C and Joslin, John and Keller, Charles},
title = {Structure-activity relationship of dihydropyridines for rhabdomyosarcoma},
journal = {Biochemical and Biophysical Research Communications},
year = {2023},
doi = {10.1016/j.bbrc.2023.04.114}
}
EUVIMED